Diabetes Care：改善血糖控制，Dulaglutide优于二甲双胍

2014-05-26 CMT 中国医学论坛报手机报

一项多国联合研究(AWARD-3研究)显示，每周一次胰高血糖素-1受体激动剂Dulaglutide在2型糖尿病患者血糖控制方面优于二甲双胍，两者安全性相似。论文5月19日在线发表于《糖尿病护理》(Diabetes Care)杂志。这项52周双盲研究将患者分为dulaglutide 1.5 mg组、dulaglutide 0.75 mg组和二甲双胍组，旨在比较dulaglutide与二甲双胍治疗

一项多国联合研究(AWARD-3研究)显示，每周一次胰高血糖素-1受体激动剂Dulaglutide在2型糖尿病患者血糖控制方面优于二甲双胍，两者安全性相似。论文5月19日在线发表于《糖尿病护理》(Diabetes Care)杂志。

这项52周双盲研究将患者分为dulaglutide 1.5 mg组、dulaglutide 0.75 mg组和二甲双胍组，旨在比较dulaglutide与二甲双胍治疗2型糖尿病患者的有效性和安全性。

结果为，26周时，糖化血红蛋白(HbA1C)较基线变化在dulaglutide 1.5 mg组为-0.78%，在dulaglutide 0.75 mg组为-0.71%，在二甲双胍组为-0.56%，dulaglutide 1.5 mg组和dulaglutide0.75 mg组均优于二甲双胍组(单侧P均<0.025)，且HbA1C达标(<7.0%和≤6.5%)的患者比例均大于二甲双胍组(P均<0.05)。3组均没有报告严重低血糖。

原始出处：

Umpierrez G1, Povedano ST2, Manghi FP3, Shurzinske L4, Pechtner V5.Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3).Diabetes Care. 2014 May 19. pii: DC_132759. [Epub ahead of print]

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=20826, encodeId=45b1208268b, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=210, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:50:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759451, encodeId=80401e5945118, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 15 20:57:00 CST 2014, time=2014-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901213, encodeId=bbf4190121381, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 29 07:57:00 CST 2014, time=2014-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763302, encodeId=2f981e6330291, content=<a href='/topic/show?id=9f4b63262b' target=_blank style='color:#2F92EE;'>#Dulaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6326, encryptionId=9f4b63262b, topicName=Dulaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=264037462481, createdName=h.y200607_23674430, createdTime=Thu Dec 11 06:57:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636876, encodeId=f27116368e696, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 02 12:57:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272906, encodeId=61a912e2906c1, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Wed May 28 01:57:00 CST 2014, time=2014-05-28, status=1, ipAttribution=)]
2015-04-11 x35042875

国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间

210 0
[GetPortalCommentsPageByObjectIdResponse(id=20826, encodeId=45b1208268b, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=210, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:50:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759451, encodeId=80401e5945118, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 15 20:57:00 CST 2014, time=2014-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901213, encodeId=bbf4190121381, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 29 07:57:00 CST 2014, time=2014-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763302, encodeId=2f981e6330291, content=<a href='/topic/show?id=9f4b63262b' target=_blank style='color:#2F92EE;'>#Dulaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6326, encryptionId=9f4b63262b, topicName=Dulaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=264037462481, createdName=h.y200607_23674430, createdTime=Thu Dec 11 06:57:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636876, encodeId=f27116368e696, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 02 12:57:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272906, encodeId=61a912e2906c1, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Wed May 28 01:57:00 CST 2014, time=2014-05-28, status=1, ipAttribution=)]
2014-07-15 智智灵药

#BET#

75 0
[GetPortalCommentsPageByObjectIdResponse(id=20826, encodeId=45b1208268b, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=210, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:50:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759451, encodeId=80401e5945118, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 15 20:57:00 CST 2014, time=2014-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901213, encodeId=bbf4190121381, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 29 07:57:00 CST 2014, time=2014-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763302, encodeId=2f981e6330291, content=<a href='/topic/show?id=9f4b63262b' target=_blank style='color:#2F92EE;'>#Dulaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6326, encryptionId=9f4b63262b, topicName=Dulaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=264037462481, createdName=h.y200607_23674430, createdTime=Thu Dec 11 06:57:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636876, encodeId=f27116368e696, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 02 12:57:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272906, encodeId=61a912e2906c1, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Wed May 28 01:57:00 CST 2014, time=2014-05-28, status=1, ipAttribution=)]
2014-10-29 木头人513

#Diabetes#

72 0
[GetPortalCommentsPageByObjectIdResponse(id=20826, encodeId=45b1208268b, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=210, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:50:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759451, encodeId=80401e5945118, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 15 20:57:00 CST 2014, time=2014-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901213, encodeId=bbf4190121381, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 29 07:57:00 CST 2014, time=2014-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763302, encodeId=2f981e6330291, content=<a href='/topic/show?id=9f4b63262b' target=_blank style='color:#2F92EE;'>#Dulaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6326, encryptionId=9f4b63262b, topicName=Dulaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=264037462481, createdName=h.y200607_23674430, createdTime=Thu Dec 11 06:57:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636876, encodeId=f27116368e696, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 02 12:57:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272906, encodeId=61a912e2906c1, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Wed May 28 01:57:00 CST 2014, time=2014-05-28, status=1, ipAttribution=)]
2014-12-11 h.y200607_23674430

#Dulaglutide#

73 0
[GetPortalCommentsPageByObjectIdResponse(id=20826, encodeId=45b1208268b, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=210, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:50:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759451, encodeId=80401e5945118, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 15 20:57:00 CST 2014, time=2014-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901213, encodeId=bbf4190121381, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 29 07:57:00 CST 2014, time=2014-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763302, encodeId=2f981e6330291, content=<a href='/topic/show?id=9f4b63262b' target=_blank style='color:#2F92EE;'>#Dulaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6326, encryptionId=9f4b63262b, topicName=Dulaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=264037462481, createdName=h.y200607_23674430, createdTime=Thu Dec 11 06:57:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636876, encodeId=f27116368e696, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 02 12:57:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272906, encodeId=61a912e2906c1, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Wed May 28 01:57:00 CST 2014, time=2014-05-28, status=1, ipAttribution=)]
2014-06-02 ms9608593228839890

#DIA#

74 0
[GetPortalCommentsPageByObjectIdResponse(id=20826, encodeId=45b1208268b, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=210, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:50:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759451, encodeId=80401e5945118, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 15 20:57:00 CST 2014, time=2014-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901213, encodeId=bbf4190121381, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 29 07:57:00 CST 2014, time=2014-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763302, encodeId=2f981e6330291, content=<a href='/topic/show?id=9f4b63262b' target=_blank style='color:#2F92EE;'>#Dulaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6326, encryptionId=9f4b63262b, topicName=Dulaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=264037462481, createdName=h.y200607_23674430, createdTime=Thu Dec 11 06:57:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636876, encodeId=f27116368e696, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 02 12:57:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272906, encodeId=61a912e2906c1, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Wed May 28 01:57:00 CST 2014, time=2014-05-28, status=1, ipAttribution=)]
2014-05-28 whlxd

#血糖控制#

73 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科

Diabetes Care：改善血糖控制，Dulaglutide优于二甲双胍

相关资讯

科室

工具

服务